Investigating the contributions of circadian pathway and insomnia risk genes to autism and sleep disturbances - Tesfaye, Rackeb; Huguet, Guillaume; Smiliovich, Zoe; Loum, Mor Absa; Douard, Elise; Jean-Louis, Martineau; Martinot, Jean Luc; Whelan, Rob; Desrivieres, Sylvane; Heinz, Andreas; Schumann, Gunter; Hayward, Caroline; et al. (medRxiv, 2021)
Sleep disturbance is prevalent in youth with Autism Spectrum Disorder (ASD). Researchers have posited that circadian dysfunction may contribute to sleep problems or exacerbate ASD symptomatology. However, there is limited genetic evidence of this. It is also unclear how insomnia risk genes identified through GWAS in a general population are related to ASD risk and common sleep problems like insomnia in ASD. We investigated the contribution of copy number variants (CNVs) encompassing circadian pathway genes and insomnia risk genes to ASD risk as well as parent reported sleep disturbances in children diagnosed with ASD. We studied 5860 ASD probands and 2092 unaffected siblings from the Simons Simplex Collection and MSSNG database, as well as 7463 individuals from two unselected populations (IMAGEN and Generation Scotland). We identified 320 and 626 rare CNVs encompassing circadian genes and insomnia risk genes respectively. Deletions and duplications with circadian genes were overrepresented in ASD probands compared to siblings and unselected controls. For insomnia-risk genes, deletions (but not duplications) were also associated with ASD. Results remained significant after adjusting for cognitive ability. CNVs containing circadian pathway and insomnia risk genes showed a stronger association with ASD, compared to CNVs containing other genes. Duplications containing circadian genes were associated with shorter sleep duration (22 minutes). Only insomnia risk genes intolerant to haploinsufficiency increased insomnia traits when duplicated. Overall, CNVs encompassing circadian and insomnia risk genes increase ASD risk despite small impacts on sleep disturbances.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding acknowledgments are detailed in the manuscript Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals was initially obtained by original collection sites from which we obtained approval to access data from. Ethical storage and sharing was also approved by the University of Montreal and Sainte Justine Research Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearchers can request data used in the current study by following established data access protocols for each cohort listed below: Simon Simplex Cohort https://www.sfari.org/resource/sfari-base/ MSSNG https://science.grants.autismspeaks.org/genetics/login.php IMAGEN https://imagen-europe.com/resources/imagen-project-proposal/ Generation Scotland https://www.ed.ac.uk/generation-scotland/for-researchers/access